Frequency of Stent Thrombosis Risk at 5 Years in Women Versus Men With Zotarolimus-Eluting Compared With Sirolimus-Eluting Stent by ten Haaf, M. (Monique) et al.
aDepar
dam, The
Netherland
dDepartme
France; eD
and Wome
dam, The
Cardiovasc
Santa Rosa
Nancy, Va
mus MC, R
COEUR, E
March 16,
See pa
*Corre
7044759.
E-mail
0002-9149
http://dx.doFrequency of Stent Thrombosis Risk at 5 Years in Women
Versus Men With Zotarolimus-Eluting Compared WithSirolimus-Eluting Stent
Monique ten Haaf, MDa,b, Yolande Appelman, MD, PhDa, William Wijns, MD, PhDc,
Gabriel Steg, MD, PhDd, Laura Mauri, MD, MSce, Tessa Rademaker-Havinga, MScf,
Gwenn Wetzels, MScg, Lisa Bousquette, MSh, Edoardo Camenzind, MDi, and
Eric Boersma, MSc, PhDj,k,*, for the PROTECT Steering Committee and Investigators
The prevalence of factors that are associated with an increased risk of stent thrombosistment o
Nethe
s; cCa
nt of C
epartme
n’s Ho
Netherl
ular, M
, Califo
ndoeuv
otterda
rasmus
2016; r
ge 1185
spondin
addres
/16/$ -
i.org/1(ST), including smoking, diabetes mellitus, and small stent size, is different in women and
men who underwent percutaneous coronary intervention. Thus, gender may potentially
modify the relation between stent type and the incidence of ST during long-term follow-up.
We explored the data of Patient Related Outcomes With Endeavor Versus Cypher stenting
Trial (PROTECT) to evaluate this hypothesis. PROTECT randomized 2,061 women and
6,648 men who underwent percutaneous coronary intervention for various indications to
Endeavor zotarolimus-eluting stenting (E-ZES) or Cypher sirolimus-eluting stenting
(C-SES). Dual antiplatelet therapy was prescribed for at least 3 months. Data on study end
points were collected until 5 years after randomization, including ST, death, and cardio-
vascular events. We analyzed end points and treatment effect (E-ZES vs C-SES) in relation
to gender. Women were on average 4.7 years older (65.8 vs 61.1), had a higher prevalence of
insulin-dependent diabetes mellitus, were less often smokers, and had a shorter total stent
length than men. At discharge and throughout follow-up, a slightly lower fraction of women
were using dual antiplatelet therapy. During 5-year follow-up, deﬁnite or probable ST was
observed in 36 women (1.8%) and 152 men (2.4%; log-rank p [ 0.15). E-ZES reduced the
incidence of ST compared with C-SES in women (hazard ratio 0.58) and men (hazard ratio
0.61), with no evidence of heterogeneity (p [ 0.89). In conclusion, in PROTECT, women
and men had similar cumulative incidence of ST at 5 years after stent placement. The
favorable effect of the study stent E-ZES over C-SES was not modiﬁed by gender.  2016
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0.1016/j.amjcard.2016.07.032interplay between gender, established risk factors for ST,
dual antiplatelet therapy (DAPT) use, and patient outcome
remains unclear. Against this background, we explored
the data of the large (8,709 patients) Patient Related Out-
comes With Endeavor Versus Cypher Stenting Trial
(PROTECT)2e4 to evaluate the inﬂuence of gender on the
incidence of ST (among other clinical end points) and on
the relation between DES stent type and these end points
during 5-year follow-up.Methods
PROTECT is a prospective, open-label, multicenter,
randomized, superiority trial, powered to study differences
in long-term clinical effectiveness and safety in a broad
group of coronary artery disease (CAD) patients with an
indication for PCI. Details of the trial design and the main
results have been published previously (ClinicalTrials.gov,
number NCT00476957).2e4 In short, 8,709 patients from
196 centers in 36 countries were randomized 1:1 to receive
either an Endeavor zotarolimus-eluting stent (E-ZES;
Medtronic CardioVascular, Santa Rosa, California) or a
Cypher sirolimus-eluting stent (C-SES; Cordis, Johnson &
Johnson, Warren, New Jersey) and otherwise were treatedwww.ajconline.org
Table 1
Patient characteristics by gender
Variable Women (n¼2061) Men (n¼6648) P-value
Age (years) 65.8 (10.0), 67 (59-73) 61.1 (10.6), 61 (54-69) <0.001
Body-mass index (kg/m2) 28.0 (5.1), 27.5 (24.2-31.2) 27.8 (4.3), 27.4 924.8-30.1) 0.049
Hypertension 1506 (73.1%) 4069 (61.2%) <0.001
Hyperlipidemia 1373 (66.6%) 4056 (61.0%) <0.001
Insulin dependent diabetes mellitus 199 (9.7%) 407 (6.1%) <0.001
Non-insulin dependent diabetes mellitus 445 (21.6%) 1360 (20.5%) 0.28
History of smoking 778 (37.7%) 4237 (63.7%) <0.001
Current smoker 362 (17.6%) 1820 (27.4%) <0.001
Family history premature coronary artery disease
in ﬁrst degree relative
682 (38.3%) 1918 (33.3%) <0.001
Prior myocardial infarction 353 (17.1%) 1439 (21.6%) <0.001
Prior percutaneous coronary intervention 227 (11.0%) 863 (13.0%) 0.018
Prior CABG 71 (3.4%) 352 (5.3%) <0.001
Prior heart failure 71 (3.4%) 194 (2.9%) 0.24
Prior peripheral vascular disease 102 (4.9%) 318 (4.8%) 0.77
Prior of stroke 70 (3.4%) 200 (3.0%) 0.38
Glomerular ﬁltration rate (ml/min) 79 (40%), 73 (56-93) 96 (47%), 91 (73-113) <0.001
Coronary Artery Disease/Gender Differences in Stent Thrombosis Risk at 5 Years in PROTECT Study 1179according to clinical practice. Patients aged 18 years who
underwent elective, unplanned, or emergency procedures
in native coronary arteries were eligible for enrollment if
they provided written informed consent. The main exclusion
criteria were a previous DES implantation at any time or a
previous bare-metal stent implantation in the preceding
12 months, treatment with warfarin, or similar anticoagulant
therapy. Enrollment started May 21, 2007, and was
completed on December 22, 2008. The ethical committee of
each participating center approved the study in accordance
with local regulations.
The PCI and stent implantation technique was in
accordance with the common clinical standards and the
manufacturers’ instructions. Direct stenting was at the
discretion of the operator. Staging of the procedures within
6 weeks of the initial procedure was allowed. DAPT therapy
with aspirin and clopidogrel (75 mg) or ticlopidine was
started 3 days before the procedure or through a loading
dose for patients not yet taking these medications. Post-
procedure, aspirin was to be given indeﬁnitely and clopi-
dogrel or ticlopidine therapy for a minimum of 3 months or
up to 12 months, according to device instructions for use
or guidelines.5 In accordance with clinical trial standards,
investigators were allowed to extend the duration of DAPT
or to restart thienopyridine therapy during the follow-up
period if clinically indicated.
Study end points included the incidence of ST (deﬁnite
or probable and deﬁnite), death (all-cause and cardiac),
myocardial infarction (MI; major Q-wave MI and all
nonfatal MI), and repeat coronary revascularization. ST was
deﬁned according to the Academic Research Consortium
criteria6 and was subdivided in early (0- to 30-day post-stent
implantation), late (>30 days), and very late (>12 months)
ST. An independent Clinical Events Committee adjudicated
ST, death, and MI after review of the original data sources.
Revascularizations were site reported. For this analysis, we
included end points up to 5-year follow-up.
Continuous variables are presented as both means  SD
and medians with interquartile ranges. Categorical variablesare presented as counts and percentages. The distribution of
baseline characteristics and clinical course variables were
compared by gender using the Wilcoxon 2-sample test for
continuous variables and the chi-square or Fisher’s exact
test (in case an expected value in the corresponding con-
tingency table was <5) for categorical data.
The incidences of the study end points are reported as
Kaplan-Meier estimates. Patients lost to follow-up were
considered at risk until the date of last contact, at which
point they were censored. Differences between women and
men were evaluated using 2-sided log-rank tests.
Multivariate Cox proportional hazards models were used
to obtain estimates of the relation between gender and study
end points (and E-ZES vs C-SES treatment effect) that are
adjusted for the broad range of clinical and angiographic
factors that are listed in Tables 1 and 2 and assigned
treatment, DAPT, gender  assigned treatment, and
DAPT  assigned treatment (as applicable). Because the
number of patients with possible or deﬁnite ST was limited,
only factors with p <0.5 for that end point in univariate
analysis were selected for multivariate adjustment. We
report adjusted hazard ratios with corresponding 95% con-
ﬁdence intervals.
The age distribution was considerably different between
women and men, whereas age was—not unexpectedly—
related with the incidence of study end points. Hence, age
was a major confounder of gender-outcome relations.
Therefore, apart from applying multivariate analyses, we
decided to report various results in 5 (clinically relevant)
strata according to age.
A 2-sided p value <0.05 was considered statistically
signiﬁcant. Analyses were performed using SAS software,
version 9.3 (SAS Institute, Cary, North Carolina).
Results
PROTECT enrolled 2,061 (23.7%) women and 6,648
men who underwent PCI (Table 1). Women and men had a
different age distribution (Figure 1). Women were on
Table 2
Angiographic and procedural characteristics
Women (n¼2061) Men (n¼6648) P-value
Indication* <0.001
Stable angina pectoris 1014 (49.2%) 3243 (48.8%)
Unstable angina pectoris 438 (21.3%) 1200 (18.1%)
ST-elevation myocardial infarction 148 (7.2%) 592 (8.9%)
Non ST-elevation myocardial infarction 364 (17.7%) 1149 (17.3%)
Silent ischemia 97 (4.7%) 464 (7.0%)
Lesion location† <0.001
Left anterior descending coronary artery 47.9% 46.2%
Right coronary artery 31.6% 28.9%
Circumﬂex artery 19.5% 23.7%
Lesion length (mm)†z 17.07 (8.94), 15 (10-20) 17.88 (9.23), 15 (12-22) <0.001
Stenosis pre procedure (%)†z 81.98 (13.15), 74 (83-92) 83.02 (12.76), 75 (85-92) <0.001
Minimal lumen diameter (mm)†z 0.52 (0.38), 0.5 (0.2-0.8) 0.50 (0.38), 0.5 (0.2-0.7) 0.038
Reference vessel diameter (mm)†z 2.90 (0.46), 3.0 (2.5-3.1) 2.99 (0.47), 3.0 (2.7-3.5) <0.001
Bifurcation† 441 (15.6%) 1574 (16.6) 0.20
Calciﬁcation 0.25
Non/mild 2033 (72.0%) 6695 (70.8%)
Moderate 616 (21.8%) 2179 (23.0%)
Severe 176 (6.2%) 588 (6.2%)
Tortuosity 0.16
Non 2207 (78.2%) 7270 (76.8%)
Moderate 549 (19.4%) 1964 (20.8%)
Severe 68 (6.2%) 226 (2.4%)
Number of lesions treated per patient* 0.032
0-1 1468 (72.1%) 4585 (69.0%)
2 434 (21.1%) 1508 (22.7%)
3 112 (5.4%) 422 (6.3%)
4 29 (1.4%) 130 (2.0%)
Number of vessels treated per patient* 0.015
0-1 1705 (82.7%) 5357 (80.6%)
2 333 (16.2%) 1160 (17.5%)
3 23 (1.1%) 128 (1.9%)
Number of stents per patient* 0.032
0-1 1287 (62.4%) 3927 (59.1%)
2 492 (23.9%) 1733 (26.1%)
3 188 (9.1%) 617 (9.3%)
4 94 (4.6%) 368 (5.5%)
Stent diameter (mm)xz 2.91 (0.40), 3.0 (2.5-3.0) 3.00 (0.52), 3.0 (2.75-3.5) <0.001
Minimal stent diameter per patient (mm)*z 2.86 (0.40), (2.75-2.50-3.00) 2.93 (0.41), 3.00 (2.50-3.00) <0.001
Total stent length per patient (mm)*z 29.52 (19.42), 24 (18-36) 31.77 (21.15), 24 (18-41) <0.001
Staged procedure* 77 (3.7%) 289 (4.3%) 0.23
Lesion success{† 2772 (99.5%) 9265 (99.5%) 0.99
Procedure successk* 1951 (96.3%) 6328 (97.2%) 0.038
* 2061 Women, 6648 men.
† Per lesion; 2825 lesions in women, 9465 lesions in men.
zMean (SD), median (interquartile range).
x 3219 stents in women, 10,832 stents in men.
{ Attainment of less than 50% residual stenosis of the target lesion with any percutaneous method.
k Attainment of less than 50% residual stenosis of all the target lesions and no inhospital major adverse cardiac events.
1180 The American Journal of Cardiology (www.ajconline.org)average 4.7 years older (mean age 65.8 vs 61.1 year,
p <0.001) and had a higher prevalence of traditional CAD
risk factors, including hypertension (73.1% vs 61.2%,
p <0.001), hyperlipidemia (66.6% vs 61.0%, p <0.001),
and insulin-dependent diabetes mellitus (9.7% vs 6.1%,
p <0.001) but a lower prevalence of smoking (37.8% vs
63.7%, p <0.001) and history of MI, PCI, or CABG.
Likewise, women had a lower mean glomerular ﬁltration
rate (79 vs 96 ml/min, p <0.001) than men. A total of 53.9%
women and 55.8% men underwent the index PCI for stableor silent angina, whereas the remaining patients were treated
for acute coronary syndromes.
Women had slightly fewer lesions requiring intervention
than men: on average, 1.37 lesions in women versus 1.42
in men (Table 2). Most lesions were located in the left
anterior descending coronary artery (47.9% in women and
46.2% in men). There were no signiﬁcant differences in the
degree of calciﬁcation of lesions and tortuosity. Women had
shorter (17.1 vs 17.9 mm, p <0.001) and less constricted
lesions (82% vs 83%, p <0.001), and the average stent
Figure 1. PROTECT study patients by gender and age. (A) Percentage of the total study sample by gender. (B) Percentage of women per age stratum.
Coronary Artery Disease/Gender Differences in Stent Thrombosis Risk at 5 Years in PROTECT Study 1181diameter (2.9 vs 3.0 mm, p <0.001) and the minimal stent
diameter (2.86 vs 2.93, p <0.001) were smaller and total
stent length (29.5 vs 31.8 mm, p <0.001) shorter than in
men. There were no differences in predilation. In women,
less often a multivessel treatment was performed (17.3% vs
19.4%, p ¼ 0.033), and fewer stents were implanted. The
success rate per lesion was similar in women and men,
although procedural success was somewhat lower in women
(96.3% vs 97.2%, p ¼ 0.038).
During the PCI procedure, combined antithrombin ther-
apy with heparin or lowemolecular weight heparin (95.0%
vs 96.1%, p ¼ 0.019) was less often given to women than
men. Women received more often direct thrombin inhibitors
like bivalirudin (4.6% vs 3.8%, p ¼ 0.15), although
this difference was nonsigniﬁcant. Glycoprotein IIb/IIIa
inhibitors (15.7% vs 18.9%, p <0.001) were less often
administered to women than to men.
At discharge up to 3 years, the use of aspirin was similar
in women and men. Thereafter, fewer women than men
used aspirin, especially in patients >80 years (Figure 2).
DAPT was applied (slightly) less frequent in women than in
men at the time of discharge (95.7% vs 96.6%, p ¼ 0.042).
The fraction of women on DAPT remained systematically
lower during follow-up, in particular in patients <50 years.
Table 3 and Figure 3 show the end points in women and
men. At 5 years, the end point of deﬁnite or probable STwas reached in 1.8% of women and 2.4% of men. In all age
strata, women had slightly lower incidence of deﬁnite or
probable ST (Figure 4). There were no differences in the
incidence of early, late, and very late ST between women
and men. The same was observed for deﬁnite ST. During
follow-up, there were signiﬁcantly more revascularizations
in men, largely explained by a higher number of target
vessel revascularizations. Target lesion revascularization
was performed in 5.8% of men and 5.3% of women. Most
revascularizations happened in the ﬁrst 2 years after the
initial procedure. No differences were found between
women and men with respect to the other end points
including all-cause death, cardiac death, MI, and composed
end points. After multivariate adjustment for age and other
risk factors, women had signiﬁcant lower incidence of death
during 5-year follow-up than men, but the incidences of
other end points were similar (Figure 3).
As a result of the randomization process, 1,017 (49.3%)
women and 3,340 (50.2%) men were allocated to treatment
with E-ZES. In women and men, E-ZES was consistently
associated with lower risk of deﬁnite or probable ST,
death, MI, the composite of death and MI, and the com-
posite of death, MI, and ST (Figure 5). In particular, the
incidence of deﬁnite or probable ST was reduced by 42%
in women and by 39% in men, with no evidence whatso-
ever of treatment heterogeneity. The gender  allocated
Figure 2. Aspirin and DAPT by gender at different age strata. The thin and thick lines represent women and men, respectively, and the triangular and circular
markers represent aspirin and DAPT, respectively.
1182 The American Journal of Cardiology (www.ajconline.org)treatment (E-ZES vs C-SES) interaction was nonsigniﬁcant
for all end points.
Discussion
The present study performed on the data of PROTECT,
a large prospective international randomized trial comparing
2 DES types with different vascular healing characteristics,
did not reveal gender differences in the incidence of ST
and other major clinical cardiovascular end points over a
follow-up period of 5 years after stent placement. The
favorable long-term effect of E-ZES over C-SES, which we
reported earlier,3,4 was consistently found in women and
men of all ages.
The age distribution differed markedly between the
genders, and women were on average almost 5 years older
than men. This observation underscores epidemiologic
studies reporting that CAD will become manifest later in life
in women than in men.7 Because (advanced) age is one of
the determinants of (an increased risk of) the incidence of
ST among other cardiovascular outcomes, age must be
considered a confounder of the gender-outcome relations,
and therefore, it is expedient to perform stratiﬁed analyses
according to age.8
In PROTECT, per age class, women had consistently
slightly better outcomes than men, although we mayconsider the small observed differences as possible statisti-
cal artifacts. Still, the >2-fold lower ST incidence in women
<50 years is remarkable—in particular, because the DAPT
use was also lower—and warrants further investigations in
larger series with detailed information on women-speciﬁc
factors. It is a well-accepted knowledge that premeno-
pausal women are (relatively) protected against CAD pro-
gression because of higher estrogen levels.9 We do not
exclude the possibility that thrombogenicity in women with
established CAD might also be age dependent because of
hormonal inﬂuences.
Women not only were older but also had a higher
prevalence of “classical” CAD risk factors including
hypertension, hyperlipidemia, and diabetes. Furthermore,
women had somewhat less well-preserved kidney function
as their glomerular ﬁltration rate was lower than men, albeit
largely in the normal range. These ﬁndings concur with
previous studies in CAD patients.10,11 Also, we found a
relatively high number of women with a history of PCI and
CABG, suggesting that PROTECT enrolled a sample of
women with a very high cardiovascular risk proﬁle
compared with previous observational studies with unse-
lected real-world CAD patients.10e12
In particular, diabetes and impaired kidney function are
known prothrombotic factors for late and very late ST with
the subsequent risk of MI and death.13,14 In addition, the
Figure 3. Kaplan-Meier estimates, crude and adjusted hazard ratios with correspon
or probable ST; (B) death; (C) death and MI; (D) death, MI, and deﬁnite or prob
Table 3
Clinical outcome at 5 years
Variable Women
(n¼2061)
Men
(n¼6648)
P-value
Deﬁnite or probable stent
thrombosis
36* (1.8%) 152 (2.4%) 0.16
Early 10 (0.5%) 47 (0.7%) 0.28
Late 7 (0.3%) 16 (0.2%) 0.43
Very late 20 (1.0%) 89 (1.4%) 0.21
Deﬁnite stent thrombosis 25 (1.3%) 98 (1.5%) 0.41
Early 7 (0.4%) 27 (0.4%) 0.84
Late 3 (0.2%) 9 (0.1%) 1.00
Very late 16 (0.8%) 62 (1.0%) 0.59
All cause death 151 (7.5%) 458 (7.0%) 0.44
Cardiac death 78 (3.9%) 245 (3.8%) 0.78
Myocardial infarction† 113 (5.6%) 372 (5.8%) 0.92
Death, myocardial infarction 241 (11.9%) 763 (11.7%) 0.67
Death, myocardial infarction,
stent thrombosis
246 (12.2%) 781 (12.0%) 0.69
Revascularizationz 304 (15.4%) 1153 (18.0%) 0.011
Major adverse cardiac eventsx 420 (20.9%) 1481 (22.8%) 0.13
Kaplan-Meier estimates for clinical outcome at 5 years.
* 1 Female patient had both early and very late stent thrombosis.
† According to historical WHO deﬁnition, based on total creatine kinase
measurements.
z Revascularization after initial procedure, including target lesion revas-
cularization, target vessel revascularization and non-target vessel revascu-
larization through percutaneous coronary intervention or coronary artery
bypass graft surgery.
x Including deﬁnite or probable stent thrombosis, cardiac death,
myocardial infarction (historical deﬁnition) and revascularization.
Coronary Artery Disease/Gender Differences in Stent Thrombosis Risk at 5 Years in PROTECT Study 1183effect of diabetes on the risk of restenosis10 and clinical
outcomes is more deleterious in women than in men.15
Nevertheless, we found similar outcomes in women and
men. Possibly, the clinical trial design with a controlled
environment contributed to this result. Another explanation
might be that prothrombotic factors and protective factors
balanced out in the women and men participating in
PROTECT. In this respect, it is important to emphasize that
there were differences in the indication for the index PCI.
Women presented more often with unstable angina and less
often with ST-segment elevation myocardial infarction then
men, and it is well known that the thrombogenic state in an
STEMI setting is higher than in other acute coronary syn-
drome phenotypes.16 Furthermore, in women, a lower
number of lesions and coronary arteries were treated than
in men. Subsequently, a lower number of stents were
implanted, which, obviously, reduces the overall incidence
of stent-related complications and in particular thrombosis.
Of note, however, is that these results were obtained despite
a lower use of DAPT in women than in men, suggesting
again a lower thrombogenicity in the studied women col-
lective potentially also because of higher age and lower
thrombocyte turnover rate.
The safety and efﬁcacy beneﬁts of DES with strong
inhibitory properties—as ﬁrst-generation DES—with regard
to angiographic outcomes and repeat revascularizations were
similar in women andmen at 1-year follow-up comparedwith
bare-metal stent in previous randomized controlled trials.17,18
PROTECT, as well as the SORT OUT (Scandinavian
Organization for Randomized Trials With Clinicalding 95% conﬁdence intervals for outcome according to gender. (A) Deﬁnite
able ST. The black and gray lines represent women and men, respectively.
Figure 5. Effect of stent type in women versus men. CI ¼ conﬁdence interval; HR ¼ hazard ratio; M ¼ men; W ¼ women.
Figure 4. Kaplan-Meier estimates for deﬁnite or probable ST according to gender and age stratum up to 5 years after randomization. (AeE) Deﬁnite or probable
ST according to age stratum. The thin and thick lines represent women and men, respectively. (F) Absolute % of deﬁnite or probable ST according to gender
and age stratum at 5 years.
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Coronary Artery Disease/Gender Differences in Stent Thrombosis Risk at 5 Years in PROTECT Study 1185Outcome) IV and V trials, did not reveal a gender interac-
tion between women and men independently of the second-
generation DES types (E-ZES, C-SES, and everolimus- or
biolimus-eluting stent).19,20 The ﬁnding is not self-evident
because stent materials might have variable effects in
women and men. For example, several studies have sug-
gested enhanced neointimal suppression after E-ZES
implantation in women compared with men,21,22 a ﬁnding
that is not reported after C-SES. Apparently, these differ-
ential effects between 2 DES types do not have impact on
clinical end points, including ST.
DAPT, consisting of aspirin plus a P2Y12 receptor
antagonist, is recommended after DES implantation for 6 to
12 months by European guidelines, followed by life-long
aspirin monotherapy.5 In PROTECT, w1 in each 4
patients still used DAPT 5 years after the index stent
placement, whereas 9 in each 10 patients used aspirin.
Slightly fewer women than men used DAPT or aspirin
during long-term follow-up. We may speculate that the
observed differences might be a result of aspirin intolerance
or active bleeding, which, in other studies, are more often
seen in women.23,24 Especially in women <50, heavy
menstrual bleeding may have led to lower DAPT adherence.
Also, long-term maintenance of DAPT was according to the
protocol physician driven and, thus, more likely to be
interrupted in a hemorrhagic-prone elderly with lower BMI
subset as in women.23,24 In an earlier report of PROTECT,
based on the 3-year follow-up data, the incidence of ST was
lower with E-ZES versus C-SES in the absence of DAPT,
whereas no difference was found in the presence of DAPT.4
The present study was based on a randomized trial, and
consequently, internal validity is high, especially for the
estimated treatment effects of E-ZES versus C-SES.
External validity, however, very much depends on patient
selection. In particular with respect to the relation between
gender and clinical outcomes, our data are as good as
observational studies, albeit that the data quality can be
considered higher than average because data are collected in
well-controlled clinical settings and are extensively moni-
tored. We realize that inclusion in PROTECT was targeted
to patients who are referred to a cathlab for PCI. Possible
gender differences in diagnosis and referral for revascular-
ization could, therefore, not been taken into account, and
thus, generalized conclusions in that direction cannot be
drawn. Also, importantly, the number of young women and
men with clinical end points was low, so that effects could
only be estimated with limited precision. Finally, not all
predictors of ST were recorded. In particular, no detailed
information was available on the PCI procedure, such as, for
example, on (under) sizing of the implanted stent, which
most likely has been different in women and men.
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